Scolnick also reviewed the progress of certain projects in the research pipeline, including VIOXX, as well as another COX-2 inhibitor, the substance P program for depression and
chemotherapy-induced emesis, and other compounds for bacterial infections, asthma, several types of cancer, and infant diarrhea.
22, 1999--Based on data published in yesterday's issue of The New England Journal of Medicine, Merck announced today it will begin Phase III large-scale clinical studies with MK-869 (L-754,030) for the treatment of
chemotherapy-induced emesis this year.